Company Profile
Clene Inc. Stock Price, News & Analysis
- Ticker:
- CLNN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.99 USD (-8.61%)
Close
Last updated: July 28, 2026
75M USD
Market cap
Why the stock is moving
As of Jul 28, 2026, CLNN closed down 8.61% at $4.99. No new same-company headline was identified in the current news window.
Company overview
Business overview
Clene is a neuroscience company focused on neurodegenerative disease and mitochondrial biology. Its programs target severe CNS disorders where disease modification would matter a great deal.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Clene sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, safety, and the ability to create a credible neurodegeneration story.
Position Within the Biotechnology Landscape
Clene is a high-catalyst neuroscience name whose valuation is tightly tied to clinical outcomes.
Future catalysts
Clene’s catalysts are CNM-Au8 and any neurodegeneration or multiple-sclerosis update that helps prove the platform still has a real clinical path. The stock remains highly data-sensitive.
Recent news
- 01
- 02
Clene Announces $7 Million Underwritten Offering of Common Stock
Source: Clene Inc.
- 03
Clene to Present at Upcoming May Conferences
Source: Clene Inc.
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Clene Inc. (CLNN)?
Clene Inc. (CLNN) most recently closed at 4.99 USD, a -8.61% move versus the previous session.
What is the market cap of Clene Inc. (CLNN)?
Clene Inc. currently has a market capitalization of 75M USD on BioPharmSignal.
What does Clene Inc. do?
Clene is a neuroscience company focused on neurodegenerative disease and mitochondrial biology. Its programs target severe CNS disorders where disease modification would matter a great deal.
On which exchange is CLNN stock listed?
Clene Inc. (CLNN) is associated with NASDAQ, United States, Biopharma.
What is Clene?
Clene’s catalysts are CNM-Au8 and any neurodegeneration or multiple-sclerosis update that helps prove the platform still has a real clinical path.
Which conditions is Clene Inc. targeting with Clene?
Clene Inc. is associated with neuroscience based on its company overview and current catalyst commentary.
How does Clene Inc. describe recent progress with Clene?
Clene’s catalysts are CNM-Au8 and any neurodegeneration or multiple-sclerosis update that helps prove the platform still has a real clinical path.
What is CNM-Au8?
Clene’s catalysts are CNM-Au8 and any neurodegeneration or multiple-sclerosis update that helps prove the platform still has a real clinical path.